23 Nov 2021
Delaware Supreme Court Refused to Swallow The Williams Companies’ Poison Pill
In The Williams Companies, Inc. v. Wolosky, the Delaware Supreme Court affirmed the Delaware Chancery Court’s ruling, in favor of stockholders, that the board of The Williams Companies failed to demonstrate that its adoption of a so-called “poison pill” was a reasonable response to a specific stockholder activist threat. The Williams Companies board adopted the disputed shareholder rights plan at the outset of the COVID-19 pandemic in response to volatile energy prices and uncertainties caused by the pandemic. The unprecedented plan included extreme features, including a 5% trigger and a broad “acting in concert” provision. Check out this article discussing the Delaware Chancery Court’s opinion.
Related Content
- Preparing in Advance for Unsolicited Bids and Shareholder Activist Proposals Checklist
Take these steps to prepare for and respond to unsolicited bids and shareholder activist proposals.
- Shelf Rights Plans and Other Strategies to Enhance the Defensibility of Rights Plans
Learn more about stockholder rights plans and legal considerations when drafting and adopting such plans.
- Rights Plans: Current Developments in the Application of Derivative Arrangements and Parallel Action by Share Accumulators
Find out how shareholder activists are circumventing rights plans.
- Shareholder Rights Agreement (Poison Pill) (DE)
Draft a stockholder rights plan using this annotated form for guidance.
Practical Guidance Updates
Featuring the latest updates from your Practical Guidance account.
- Practical Guidance Journal Fall 2021 Edition features Environmental, Social, and Governance guidance.
- Check out the new Practical Guidance Author Center! Learn about the 1500+ leading attorney authors contributing to our 20 practice areas, and find out how you can Become a Practical Guidance Author.
- Document alert sallow you to stay current on legal developments that affect your practice. Find out how to set up your document alerts.
Experience results today with practical guidance, legal research, and data-driven insights—all in one place.
Experience Lexis+